Sun Min Lim

4.3k total citations
132 papers, 2.8k citations indexed

About

Sun Min Lim is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sun Min Lim has authored 132 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Pulmonary and Respiratory Medicine, 77 papers in Oncology and 35 papers in Molecular Biology. Recurrent topics in Sun Min Lim's work include Lung Cancer Treatments and Mutations (79 papers), Lung Cancer Research Studies (32 papers) and Cancer Genomics and Diagnostics (19 papers). Sun Min Lim is often cited by papers focused on Lung Cancer Treatments and Mutations (79 papers), Lung Cancer Research Studies (32 papers) and Cancer Genomics and Diagnostics (19 papers). Sun Min Lim collaborates with scholars based in South Korea, United States and Singapore. Sun Min Lim's co-authors include Byoung Chul Cho, Ross A. Soo, Hye Ryun Kim, Nicholas Syn, Hyo Sup Shim, Joo-Hang Kim, Min Hee Hong, Kyoung‐Ho Pyo, Sun Young Rha and Myung‐Ju Ahn and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sun Min Lim

123 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sun Min Lim South Korea 27 1.6k 1.5k 900 521 229 132 2.8k
Koichi Minato Japan 29 1.6k 1.0× 2.1k 1.4× 781 0.9× 364 0.7× 252 1.1× 171 3.1k
Luís Manso Spain 22 1.6k 1.0× 1.9k 1.3× 710 0.8× 802 1.5× 132 0.6× 153 3.3k
Kathryn A. Gold United States 29 1.8k 1.1× 2.1k 1.4× 922 1.0× 463 0.9× 448 2.0× 99 3.5k
Keisuke Aoe Japan 31 2.1k 1.3× 1.5k 1.0× 872 1.0× 587 1.1× 184 0.8× 105 3.4k
Yuanyuan Zhao China 29 1.1k 0.7× 1.9k 1.3× 558 0.6× 533 1.0× 251 1.1× 162 3.0k
Yusuke Okuma Japan 24 936 0.6× 1.6k 1.0× 549 0.6× 273 0.5× 260 1.1× 186 2.5k
Alan H. Bryce United States 26 1.3k 0.8× 1.0k 0.7× 642 0.7× 545 1.0× 140 0.6× 167 2.5k
Stefania Gori Italy 30 897 0.5× 2.0k 1.4× 680 0.8× 694 1.3× 234 1.0× 180 3.5k
Óscar Juan Spain 22 1.3k 0.8× 1.4k 0.9× 526 0.6× 378 0.7× 204 0.9× 154 2.2k
Kathleen C. Torkko United States 29 916 0.6× 900 0.6× 661 0.7× 424 0.8× 193 0.8× 46 2.6k

Countries citing papers authored by Sun Min Lim

Since Specialization
Citations

This map shows the geographic impact of Sun Min Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sun Min Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sun Min Lim more than expected).

Fields of papers citing papers by Sun Min Lim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sun Min Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sun Min Lim. The network helps show where Sun Min Lim may publish in the future.

Co-authorship network of co-authors of Sun Min Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Sun Min Lim. A scholar is included among the top collaborators of Sun Min Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sun Min Lim. Sun Min Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lim, Sun Min, Jianjun Zhang, Nir Peled, et al.. (2025). 58P: Subcutaneous (SC) after intravenous (IV) amivantamab in advanced NSCLC: Initial results from PALOMA-2. Journal of Thoracic Oncology. 20(3). S46–S47.
2.
Lim, Sun Min, et al.. (2024). Real-world outcomes with lurbinectedin in second-line and beyond for small cell lung cancer in Korea.. Journal of Clinical Oncology. 42(23_suppl). 211–211.
3.
4.
Lim, Sun Min, Josiane Mourão Dias, Pei Jye Voon, et al.. (2024). Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.. Journal of Clinical Oncology. 42(17_suppl). LBA8612–LBA8612. 3 indexed citations
5.
Kim, Jae Hwan, Kyoung‐Ho Pyo, Young Seob Kim, et al.. (2024). Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing. PLoS ONE. 19(2). e0294857–e0294857. 4 indexed citations
6.
Hong, Moonki, Sang Wook Lee, Byoung Chul Cho, et al.. (2024). Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy response. Therapeutic Advances in Medical Oncology. 16. 12698954–12698954.
7.
8.
Lee, You Won, Jii Bum Lee, Min Hee Hong, et al.. (2024). Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. Clinical Cancer Research. 30(8). 1582–1594. 10 indexed citations
9.
Lim, Sun Min, Hee Kyung Ahn, Yun‐Gyoo Lee, et al.. (2023). A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial. Cancer Research and Treatment. 56(1). 37–47. 4 indexed citations
10.
Lim, Sun Min, et al.. (2023). Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations. Therapeutic Advances in Medical Oncology. 15. 4287558163–4287558163. 13 indexed citations
11.
Lee, Jii Bum, Hyung Soon Park, Su Jin Choi, et al.. (2022). Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. Therapeutic Advances in Medical Oncology. 14. 4287553793–4287553793. 3 indexed citations
12.
Lee, Jiyun, Zofia Piotrowska, Ross A. Soo, Byoung Chul Cho, & Sun Min Lim. (2022). Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. Therapeutic Advances in Medical Oncology. 14. 4287556131–4287556131. 8 indexed citations
13.
Lee, You Won, Jae Hwan Kim, YoungJoon Park, et al.. (2022). Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC. Clinical Cancer Research. 29(1). 221–232. 35 indexed citations
14.
Kim, Seok‐Young, Sang-Min Kim, Su-Min Lim, et al.. (2021). Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. Clinical Cancer Research. 27(15). 4397–4409. 88 indexed citations
15.
Kim, Jae Hwan, Young Seob Kim, Mi Ran Yun, et al.. (2021). Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor. Yonsei Medical Journal. 63(1). 42–42. 10 indexed citations
16.
Kim, Miso, Bhumsuk Keam, Chan‐Young Ock, et al.. (2020). Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07. Thoracic Cancer. 11(12). 3482–3489. 19 indexed citations
17.
Pyo, Kyoung‐Ho, Sun Min Lim, Jae Hwan Kim, et al.. (2020). Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer. Journal for ImmunoTherapy of Cancer. 8(2). e000970–e000970. 23 indexed citations
18.
Lim, Sun Min, Jae Woo Choi, Min Hee Hong, et al.. (2019). Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. Lung Cancer. 131. 139–146. 26 indexed citations
19.
Pyo, Kyoung‐Ho, et al.. (2018). Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. Lung Cancer. 127. 112–121. 34 indexed citations
20.
Kang, Chan Woo, Jinyoung Sohn, Sung‐Moo Kim, et al.. (2015). Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET -Rearranged Lung Adenocarcinoma. Molecular Cancer Therapeutics. 14(10). 2238–2248. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Koichi Minato Breakdown of academic impact, for papers by Luís Manso Breakdown of academic impact, for papers by Kathryn A. Gold Breakdown of academic impact, for papers by Keisuke Aoe Breakdown of academic impact, for papers by Yuanyuan Zhao Breakdown of academic impact, for papers by Yusuke Okuma Breakdown of academic impact, for papers by Alan H. Bryce Breakdown of academic impact, for papers by Stefania Gori Breakdown of academic impact, for papers by Óscar Juan Breakdown of academic impact, for papers by Kathleen C. Torkko
Rankless by CCL
2026